{"id":"NCT03736447","sponsor":"Aimmune Therapeutics, Inc.","briefTitle":"Peanut Oral Immunotherapy Study of Early Intervention for Desensitization","officialTitle":"Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-27","primaryCompletion":"2022-07-05","completion":"2022-07-05","firstPosted":"2018-11-09","resultsPosted":"2023-03-02","lastUpdate":"2023-03-02"},"enrollment":146,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Peanut Allergy"],"interventions":[{"type":"BIOLOGICAL","name":"AR101 powder provided in capsules & sachets","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo powder provided in capsules & sachets","otherNames":[]}],"arms":[{"label":"AR101 powder provided in capsules & sachets","type":"ACTIVE_COMPARATOR"},{"label":"Placebo powder provided in capsules & sachets","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to \\< 4 years.","primaryOutcome":{"measure":"Percentage of Subjects Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC)","timeFrame":"12 months","effectByArm":[{"arm":"AR101","deltaMin":73.5,"sd":null},{"arm":"Placebo","deltaMin":6.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":23,"countries":["United States","France","Germany","United Kingdom"]},"refs":{"pmids":["38320526"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":98},"commonTop":["Urticaria","Cough","Pyrexia","Vomiting","Rhinorrhoea"]}}